FDA approves Roche MMR test as a companion diagnostic

Create PDF

“We are excited to launch this companion diagnostic test with GSK to help recurrent or advanced endometrial cancer patients with limited treatment options,” Thomas Schinecker, CEO of Roche Diagnostics, said in a press release. “This test provides clinicians with an effective tool to identify patients best suited for treatment with GSK’s JEMPERLI, providing a new therapeutic option for women with MMR-deficient endometrial cancer whose disease progresses on or following initial chemotherapy treatment.”

The Ventana MMR RxDx Panel is a label expansion of Roche’s Ventana MMR IHC Panel.